Iovance BiotherapeuticsvsMerck & Company

IOVA and MRK stock compared: price, dividend, valuation and results, from SEC filings.

IOVA

Iovance Biotherapeutics, Inc.

$7.33

Value $3.4B

-1.94%
IOVA's page

MRK

Merck & Company, Inc.

$131.53

Value $325B

-4.57%
MRK's page

Iovance Biotherapeutics (IOVA) has a market value of $3.4B and Merck & Company (MRK) $325B. Over the last year, with dividends, IOVA moved +200.8% and MRK +40.4%. Dividend yield: IOVA none, MRK 2.59%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IOVA$3.4B

    MRK$325B

    MRK is 96 times IOVA

  • Revenue, 12 months

    IOVA$379M

    MRK$67.4B

    MRK is 178 times IOVA

  • Net income, 12 months

    IOVA-$221M

    MRK$2.5B

  • Operating margin

    IOVA-60.8%

    MRK–

  • ROIC

    IOVA-24.8%

    MRK3.9%

    28.6 points apart

  • P/E

    IOVA–

    MRK132.6

  • Dividend yield

    IOVA0.0%

    MRK2.6%

    2.6 points apart

  • 5-year return

    IOVA-61.5%

    MRK+84.5%

    146.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IOVA-61.5%

MRK+84.5%

010020020222023202420252026
Returns by period
PeriodIOVAWith dividendsMRKWith dividends
1 year since November 18, 2025+200.8%Price +200.8%+40.4%Price +36.4%
3 years since November 17, 2023+45.3%+13.3% a yearPrice +45.3%+41.7%+12.3% a yearPrice +29.3%
5 years since November 18, 2021-61.5%-17.4% a yearPrice -61.5%+84.5%+13.0% a yearPrice +58.4%
10 years since November 21, 2016+0.5%+0.1% a yearPrice +0.5%+200.2%+11.6% a yearPrice +121.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IOVAIovance BiotherapeuticsMRKMerck & Company

Valuation

IOVAMRK
Valuation
Price$7.33$131.53
Market value$3.4B$325B
Enterprise value (EV)$3.0B$369B
P/E–132.6
P/E, 5-year median–14.8
P/B4.27.2
EV/EBIT–77.6
Free cash flow yield–4.5%

Results and growth

IOVAMRK
Results and growth
Revenue, 12 months$379M$67.4B
Net income, 12 months-$221M$2.5B
Free cash flow, 12 months-$216M$14.7B
Earnings per share, 12 months-$0.50$0.98
Revenue growth, year on year60.6%1.3%
Revenue growth a year, past+1,388.7%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

IOVAMRK
Margins and returns on capital
Gross margin53.2%71.8%
Operating margin-60.8%–
Net margin-58.2%3.6%
ROIC-24.8%3.9%
ROE-30.0%5.2%

Balance sheet

IOVAMRK
Balance sheet
Cash$376M$9.7B
Total debt$45M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

IOVAMRK
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.6%
Shareholder yield–4.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IOVA or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Iovance Biotherapeutics or Merck & Company?

By market value, Merck & Company ($325B) is about 95.8 times Iovance Biotherapeutics ($3.4B), at today's prices.

How did IOVA and MRK stock do over the last 10 years?

Since November 21, 2016, IOVA's price moved +0.5% and MRK's +121.2%. With dividends: IOVA +0.5% (+0.1% a year), MRK +200.2% (+11.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, IOVA or MRK?

The dividend yield at today's price is none for Iovance Biotherapeutics and 2.59% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Iovance Biotherapeutics or Merck & Company?

Over the last twelve months, the net margin was -58.2% for Iovance Biotherapeutics and 3.6% for Merck & Company, and the operating margin -60.8% and –. Revenue was $379M and $67.4B.

Which is the better investment, Iovance Biotherapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.